Latest Breaking News On - True disease modification - Page 1 : comparemela.com

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

– Participants treated with atacicept for 72 weeks showed consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment – Placebo.

New yorkUnited statesMarshall fordyceJoyce allaireMari purpuraRichard lafayetteExchange commissionVera therapeutics incStanford glomerular disease centerStanford university medicalChief executive officerData fromAre consistent withTrue disease modificationPrivate securities litigation reform act

Vera Therapeutics (VERA) Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Vera Therapeutics (VERA) Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesRichard lafayetteMarshall fordyceVera therapeutics incVera therapeuticsStanford glomerular disease centerStanford university medicalChief executive officerData fromAre consistent withTrue disease modification

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesMari purpuraRichard lafayetteMarshall fordyceJoyce allaireVera therapeutics incExchange commissionStanford glomerular disease centerStanford university medicalChief executive officerData fromAre consistent withTrue disease modificationPrivate securities litigation reform act